Archive for the ‘wolters kluwer lippincott’ Category
In 2005, the U.S. Office of Research Integrity announced that obesity researcher Eric Poehlman had committed misconduct in 10 published papers. You might think that all of those ten articles would have been retracted a decade later.
You’d be wrong. Only six of them have. Here’s what Elizabeth Wager (a member of the board of directors of The Center For Scientific Integrity, our parent non-profit organization) found when she went looking through the record. Read the rest of this entry »
A biologist at Case Western Reserve University School of Medicine in Ohio has retracted a paper from Inflammatory Bowel Diseases after a university review found the figures within it could not be “validated by original data.”
The 2010 paper, “Elevated IL-13Rα2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway,” concerns the elevated expression and role of an inflammatory protein in colon cancer cells.
According to the notice, corresponding author and biologist Alan Levine — who recently received a $3.9 million Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse — requested the retraction.
Over a decade ago, a case report on a woman with cervical cancer and lymphoma was “published twice” by the International Journal of Gynecological Cancer within the span of a few months. The retraction note came out just now.
One copy of the paper appeared in the July 2003 issue of the journal. The second, now-retracted, copy — “Coincidental detection of T-cell rich B cell lymphoma in the para-aortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer: A case report” — was published later that year, in the September issue.
There are just a few cosmetic differences between the headlines and abstracts of the papers — a “;” instead of a “,”; a change in verb tense, and a typo, for instance. (See a text comparison of the abstracts here.)
The brief retraction note, from the journal’s Editor in Chief Uziel Beller, doesn’t explain what took so long to act on the error — just tosses the blame to whoever was in charge of the journal at the time:
A group of researchers in China and the United States have retracted a 2014 paper in the Journal of Cardiovascular Pharmacology after discovering the data were fatally flawed.
The article examined whether the anti-arrhythmia drug zacopride affected cardiac remodeling after heart attack, and came from Bo-We Wu, of Shanxi Medical University, in Taiyuan, and colleagues, including one author from Savannah, Georgia.
Here’s more from the notice for “Activation of IK1 channel by zacopride attenuates left ventricular remodeling in rats with myocardial infarction”:
A group of pain researchers in Austria has lost their 2014 paper in the European Journal of Anaesthesiology because one of the authors wasn’t, well, one of the authors.
The article, “Intravenous nonopioid analgesic drugs in chronic low back pain patients on chronic opioid treatment: A crossover, randomised, double-blinded, placebo-controlled study,” came from a team at the Medical University Vienna and Evangelical Hospital Vienna.
During the study, the authors tested whether intravenous infusions of nonopioid drugs (such as paracetamol, or Tylenol) helped people with chronic back pain who take opioids regularly. They found that people’s pain levels decreased in the days leading up to treatment, when they were receiving a placebo, but not after the actual infusion. The results likely stem from “expectation-related mechanisms,” they wrote. Read the rest of this entry »
Scientists at the National University of Singapore and the Hong Kong Polytechnic University certainly found one, but we really can’t recommend it: doing one randomized controlled trial (RCT) with several outcomes, and publishing them as three separate 2014 papers with “considerable overlap.”
So far, one paper has been retracted, and another withdrawn.
The number of papers retracted for fake peer reviews — well in excess of 100, by our count — continues to grow.
The latest to join the list are “Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials” and “Association study of TGFBR2 and miR-518 gene polymorphisms with age at natural menopause, premature ovarian failure and early menopause among Chinese Han women,” both published in 2014 in Medicine.
The Journal of Clinical Psychopharmacology has retracted a 2011 paper on depersonalization disorder by a pair of authors in Azerbaijan who got a bit too familiar with their source material without proper attribution. And the journal has offered its readers a handy — if depressingly obvious — admonition about publication ethics.
The article, “Lamotrigine in the immediate treatment of outpatients with depersonalization disorder without psychiatric comorbidity. Randomized, double-blind, placebo-controlled study,” by researchers at the Central Mental Clinic for Outpatients of Baku City, purported to find that: Read the rest of this entry »
A new editorial in the Journal of Patient Safety accuses former editor and patient safety expert Charles Denham of having undeclared conflicts of interest in nine out of ten articles he published in the journal.
Denham was at the center of massive controversy earlier this year, when the government accused him of taking more than $11 million in kickbacks from medical supply company CareFusion. Supposedly, he took the money to influence the National Quality Forum, where Denham was a co-chair of safe practices, to endorce ChloraPrep, a CareFusion antiseptic.
Organ donation in China, particularly the practice of using organs from executed prisoners, which the government pledged to stop by the middle of this year, has been a controversial subject. For a group of authors in that country and the U.S, a letter criticizing their work that introduced “the political situation of organ donation in China” was cause to retract their own paper.